文献速递慢性静脉疾病

VeClose试验12个月结果:氰基丙烯酸酯与射频消融治疗大隐静脉功能不全的比较

VeClose trial 12-month outcomes of cyanoacrylate closure versus radiofrequency ablation for incompetent great saphenous veins.
PubMed 文献 · J Vasc Surg Venous Lymphat Disord · 2017-03-06

VeClose随机试验纳入222例症状性大隐静脉功能不全患者,随机接受氰基丙烯酸酯闭合(CAC,n=108)或射频消融(RFA,n=114)。

要点

  • CAC与RFA在12个月时均实现高闭塞率(97.2% vs 97.0%)。
  • CAC组在1个月时完全闭塞率更高(100% vs 87%)。

核心结论

  • 对于大隐静脉功能不全患者,CAC和RFA均能实现高闭塞率。
  • CAC完全闭塞时间更快,再通自由率有更高趋势。
  • 两种疗法的生活质量评分改善程度相当。

研究设计与样本

  • 随机对照试验,222例症状性大隐静脉功能不全患者随机接受CAC(n=108)或RFA(n=114)。
  • 12个月随访获得192例(95例CAC,97例RFA;总随访率86.5%)。
  • 在第3个月访视后,受试者可接受针对可见静脉曲张和不功能属支的辅助治疗。
  • 使用双功超声在术后第3天及第1、3、6、12个月评估静脉闭塞。

主要发现

  • 第1个月时,CAC组100%和RFA组87%的受试者目标静脉完全闭塞。
  • 第12个月时,完全闭塞率两组几乎相同(CAC组97.2%,RFA组97.0%)。
  • 两组症状和生活质量改善程度相同。
  • 大多数不良事件为轻至中度,且与器械或操作无关。

临床怎么用

  • CAC和RFA均可作为大隐静脉功能不全的有效治疗选择。
  • CAC可能提供更快的闭塞和潜在更低的再通风险,但需权衡。
  • 术后应使用双功超声监测闭塞情况。

局限性

  • 12个月随访率为86.5%,存在失访偏倚可能。
  • 原文未报告盲法、分配隐藏等偏倚控制细节。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Endovenous cyanoacrylate closure (CAC) is a new U.S. Food and Drug Administration-approved therapy for treatment of clinically symptomatic venous reflux in saphenous veins. The device is indicated for the permanent closure of lower extremity superficial truncal veins, such as the great saphenous vein (GSV). Early results from a randomized trial of CAC have been reported previously. Herein we report 1-year outcomes. METHODS: There were 222 subjects with symptomatic GSV incompetence randomly assigned to receive either CAC (n = 108) or radiofrequency ablation (RFA; n = 114). After the month 3 visit, subjects could receive adjunctive therapies aimed at treating visible varicosities and incompetent tributaries. Vein closure was assessed at day 3 and months 1, 3, 6, and 12 using duplex ultrasound. Additional study visit assessments included the Venous Clinical Severity Score; Clinical, Etiology, Anatomy, and Pathophysiology classification; EuroQol-5 Dimension; and Aberdeen Varicose Vein Questionnaire. Both time to closure and time to first reopening of the target vein were evaluated using survival curve analysis. Adverse events were evaluated at each visit. RESULTS: Of 222 enrolled and randomized subjects, a 12-month follow-up was obtained for 192 (95 CAC and 97 RFA; total follow-up rate, 192/222 [86.5%]). By month 1, 100% of CAC subjects and 87% of RFA subjects demonstrated complete occlusion of the target vein. By month 12, the complete occlusion rate was nearly identical in both groups (97.2% in the CAC group and 97.0% in the RFA group). Twelve-month freedom from recanalization was similar in the CAC and RFA groups, although there was a trend toward greater freedom from recanalization in the CAC group (P = .08). Symptoms and quality of life improved equally in both groups. Most adverse events were mild to moderate and not related to the device or procedure. CONCLUSIONS: In patients with incompetent GSVs, treatment with both CAC and RFA results in high occlusion rates. Time to complete occlusion was faster with CAC, and freedom from reopening was higher after CAC. Quality of life scores improved equally with both therapies.

来源:J Vasc Surg Venous Lymphat Disord,查看原文。版权归原作者所有。

引用

  1. Morrison N, Gibson K, Vasquez M, et al. VeClose trial 12-month outcomes of cyanoacrylate closure versus radiofrequency ablation for incompetent great saphenous veins. J Vasc Surg Venous Lymphat Disord. 2017. PMID: 28411697. doi:10.1016/j.jvsv.2016.12.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。